April 17, 2018
AstraZeneca Japan President Stefan Woxström AstraZeneca is planning a record seven launches in Japan in 2018, including the first-in-class PARP inhibitor Lynparza (olaparib) and immuno-oncology hopeful Imfinzi (durvalumab), which it believes would catapult the company into the top league of...read more